- GlobeNewswire•2 days ago
BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 20, 2017-- Amarin Corporation plc announced today that it and its wholly owned subsidiary, Corsicanto II Designated Activity Company, have entered into separate, ...
- Reuters•3 days ago
The U.S. health regulator issued draft guidance, recommending ways to communicate promotional materials and additional information that is not on the label of medical products. The U.S. Food and Drug Administration typically determines what information goes on the labels of medical drugs and devices, after evaluating whether the product is safe and effective for the proposed indication. If a firm communicates information, including on promotional material, that has not been evaluated by the regulator, but appears to be FDA-ratified, then it could lead to misbranding, and could subject firms to enforcement action if the representations or suggestions are considered false or misleading.
- Motley Fool•10 days ago
Trump appears ready to deal a major blow to the FDA's regulatory powers. Here are two stocks that would benefit enormously from such a move.
AMRN : Summary for Amarin Corporation plc - Americ - Yahoo Finance
Amarin Corporation plc (AMRN)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||2.85 x 3000|
|Ask||3.95 x 200|
|Day's Range||2.90 - 2.97|
|52 Week Range||2.56 - 3.65|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-6.81|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|